文献速递慢性肾脏病肾小球疾病

美国IgA肾病患者CKD进展、肾衰竭与死亡情况

CKD progression, kidney failure, and mortality among US patients with IgA nephropathy.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

该回顾性纵向队列研究纳入2000至2022年Kaiser Permanente南加州医疗系统内655例经活检确诊的成人IgA肾病患者,评估以eGFR下降≥50%、肾衰竭或死亡组成的复合结局。随访期间234例(36%)达到复合结局,发生率79.4例/1000患者年,中位发生时间2.7年;基线及时间平均UPCR升高与eGFR下降≥50%/肾衰竭风险增加相关,作者认为蛋白尿≥0.5 g/g即提示肾脏结局风险升高。

要点

  • 655例IgA肾病患者中234例(36%)达到eGFR下降≥50%、肾衰竭或死亡的复合结局。
  • 复合结局发生率79.4例/1000患者年(95%CI 69.6, 90.7),中位发生时间2.7年。
  • 作者认为IgA肾病在蛋白尿≥0.5 g/g时肾脏结局风险即升高。

核心结论

  • 在这个大型、多样化队列中,相对较短的随访期内即出现高比例的肾脏结局。
  • 作者认为IgA肾病在蛋白尿水平≥0.5 g/g时即携带升高的肾脏结局风险,这与既往认为低于1 g/g为低风险的认识相反。

研究设计与样本

  • 回顾性纵向队列研究(2000-2022年),纳入Kaiser Permanente南加州医疗系统内经活检确诊的成人IgA肾病患者。
  • 共655例原发性IgA肾病患者,其中31%为亚洲/太平洋岛民,3%为黑人,40%为西班牙裔/拉丁裔,24%为白人。
  • 采用Cox比例风险回归模型估计eGFR下降/肾衰竭的风险比(HR),并校正潜在混杂因素。

主要发现

  • 234例(36%)达到复合结局,其中eGFR下降≥50%占17%、肾衰竭占16%、死亡占3%。
  • 复合结局发生率为79.4例/1000患者年(95%CI 69.6, 90.7),中位发生时间2.7年。
  • 以基线UPCR<0.5 g/g为参照,基线UPCR 0.5-<1、1-2、>2 g/g发生eGFR下降≥50%/肾衰竭的HR分别为2.4(95%CI 1.1, 5.1)、3.2(95%CI 1.5, 6.6)、5.1(95%CI 2.5, 10.4)。
  • 以时间平均UPCR<0.5 g/g为参照,时间平均UPCR 0.5-<1、1-2、>2 g/g的HR分别为5.4(95%CI 2.3, 13.0)、14.4(95%CI 16.5, 32.2)、41.2(95%CI 17.9, 94.5)。
  • 较低的基线eGFR和糖尿病与eGFR下降≥50%/肾衰竭风险升高相关,年龄≥30岁与该风险降低相关;按种族/族裔区分风险未见明确趋势。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND HYPOTHESIS: We assessed disease progression among patients with immunoglobulin A nephropathy (IgAN) and characterized factors associated with risk for adverse outcomes. METHODS: A retrospective longitudinal cohort (2000-2022) study of adults with biopsy-confirmed IgAN within Kaiser Permanente Southern California was performed. The outcome of interest was a composite of ≥50% estimated glomerular filtration rate (eGFR) decline, kidney failure, or mortality. Cox proportional hazards regression modeling was used to estimate hazard ratios (HR) for the eGFR decline/kidney failure with adjustment for potential confounders. RESULTS: Among 655 patients with primary IgAN (31% Asian/Pacific Islander, 3% Black, 40% Hispanic/Latino, 24% White), 234 (36%) reached the composite outcome of ≥50% eGFR decline (17%), kidney failure (16%), or mortality (3%). The composite outcome occurred at a rate of 79.4 events (95% confidence intervals (CI) 69.6, 90.7) per 1000 patient-years, with a median time to event of 2.7 years. Compared to urine protein creatinine ratio (UPCR) <0.5 vs 0.5-<1 g/g, 1-2, and >2 g/g, the HR (95% CI) for ≥50% eGFR decline/kidney failure were 2.4 (1.1, 5.1), 3.2 (1.5, 6.6), and 5.1 (2.5, 10.4) for baseline UPCR and 5.4 (2.3, 13.0), 14.4 (16.5, 32.2), and 41.2 (17.9, 94.5) for time-averaged UPCR. Lower baseline eGFR and diabetes were also associated with higher risk, while age ≥30 years was associated with lower risk for ≥50% eGFR decline/kidney failure. There were no clear trends differentiating risk by race/ethnicity. CONCLUSION: In this large, diverse cohort, high rates of kidney outcomes occurred within a relatively short follow-up duration. Our findings suggest that IgAN carries elevated risk for kidney outcomes starting at proteinuria levels ≥0.5 g/g, in contrast to earlier perceptions that levels below 1 g/g are associated with low risk.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Sim JJ, Chen Q, Cannizzaro N, et al. CKD progression, kidney failure, and mortality among US patients with IgA nephropathy. Nephrol Dial Transplant. 2025. PMID: 40307873. doi:10.1093/ndt/gfaf084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。